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Background
Cardiac failure in septic shock usually originates from
hypovolaemia, impaired global contractility or right ven-
tricular failure (RVF). Acute RVF due to endotoxin-
mediated pulmonary hypertension results in global
hypoperfusion. However, the treatment of pulmonary
vascular resistance (PVR) in septic patients remains a
black box.
Methods
After ethical approval, septic shock was induced in 32
pigs ( 25 ± 3 kg) by continuous infusion of endotoxin
(Escherichia coli serotype 0111:B4). The animals
received a protocol-based treatment with fluids and
vasopressors according to the surviving sepsis campaign
guidelines. Then, they were randomized to either
inhaled (i.h.) (240μgk g
-1) or intravenous (i.v.) (24μgk g
-
1) treatment with BAY 41-8543 or controls. Heart rate
(HR (bpm)), mean arterial pressure (MAP (mmHg)),
mean pulmonary artery pressure (MPAP (mmHg)), car-
diac output (CO (l min
-1)) and PVR (dyn sec cm
-5) were
assessed every 15 minutes for 1 h after starting the
treatment. Following a wash out period of 1 h, the ani-
mals were once more randomized to double dose (D2) i.
h. or i.v. respectively or to simultaneous administration
of Bay 41-8543 at a single dose together with NO (i.h.)
at 20 ppm. Hemodynamic measurements were taken for
another hour. Data are expressed as mean ± SD at
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Table 1
shock
(n=32)
i.h.
(n=12)
i.v.
(n=14)
con
(n=6)
i.h. D2
(n=6)
i.h. no
(n=5)
i.v. D2
(n=5)
i.v. no
(n=5)
con no
(n=5)
HR 127
(34)
150
(21)
163**
(28)
123
(34)
140
(35)
146
(19)
171
(29)
148
(29)
113
(34)
MAP 58
(7)
71
(7)
68
(6)
73
(8)
75
(6)
69
(9)
68
(14)
73
(10)
73
(8)
MPAP 38
(7)
40
(7)
37
(8)
44
(6)
42
(10)
42
(9)
40
(16)
37**
(9)
39**
(9)
PVR 1246
(401)
491**
(106)
469**
(198)
972
(325)
691**
(322)
573**
(245)
849*
(815)
460**
(103)
887**
(296)
CO 2.02
(0.51)
4.65**
(0.76)
5.04**
(1.43)
2.93
(0.89)
3.73
(1.71)
4.16*
(1.44)
4.3**
(2.85)
4.06**
(0.78)
2.46
(0.67)
* p<0.05 **p<0.01 vs. control group (con)
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between groups were analyzed using a linear mixed-
effects model.
Results
Both during i.h. and i.v. application of BAY 41-8543, a
significant decrease in PVR and an increase in CO was
observed. Additive inhaled NO decreased PVR more
than doubling the dose of BAY 41-8543 (Table 1).
Conclusion
The stimulator of the soluble guanylate cyclase BAY 41-
8543 offers a treatment option for pulmonary hyperten-
sion in septic shock. Both inhalative and intravenous
administration of BAY 41-8543 reduces PVR and
increase CO. Further, there seems to be an additive
effect of inhaled NO.
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